Mayo Clinic to test vaccine for providing lifelong immunity against precancerous brea
 

Only about 35 percent of precancerous breast lesions morph into cancer if untreated, but physicians cannot identify which lesions are potentially dangerous.

More...

Re: Mayo Clinic to test vaccine for providing lifelong immunity against precancerous
 

I took part in the trial for DCIS. Finished the vaccine series in October 2020. I also had the chance to view the earlier phase 1 trial for women with more advanced disease. In that trial of the 22 women who were treated, only two had a recurrence of their HER2 disease. AND one of those two had not finished the vaccine series and the other woman developed cancer in the opposite breast. I don't consider either of those a recurrence which means NONE of the women treated had a recurrence.